Myriad Genetics Inc.
MYGN | NASDAQ
$4.01
+$0.12 (+3.08%)
At close: Sep 21, 2026, 4:00 PM ET
$4.01
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 824.5M | 837.6M | 753.2M | 678.4M | 690.6M | 557M |
Cost of Revenue | 247.9M | 252.2M | 236.2M | 202M | 197.6M | 178.2M |
Gross Profit | 576.6M | 585.4M | 517M | 476.4M | 493M | 378.8M |
Operating Income | -67.8M | -87.6M | -257.4M | -118.3M | -190.5M | -194.8M |
Interest Income | 1.8M | 1.7M | 2.5M | 2.6M | 700K | 9.2M |
Pretax Income | -395.1M | -123.5M | -262.2M | -140.6M | -57.1M | -283.7M |
Net Income | -365.9M | -127.3M | -263.3M | -112M | -27.2M | -223.7M |
Selling & General & Admin | 537.6M | 560M | 572.9M | 514.7M | 537.8M | 500.7M |
Research & Development | 106.8M | 113.4M | 88.7M | 85.4M | 81.9M | 80.9M |
Other Expenses | n/a | 35.5M | 112.8M | 16.9M | 63.8M | 71.7M |
Operating Expenses | 644.4M | 708.9M | 774.4M | 617M | 683.5M | 653.3M |
Interest Expense | 10.5M | 2.8M | 2.9M | 3.2M | 6.6M | n/a |
Selling & Marketing Expenses | 280.8M | 284.1M | 289.2M | 266.8M | n/a | n/a |
Cost & Expenses | 892.3M | 925.6M | 1.01B | 796.7M | 881.1M | 831.5M |
Income Tax Expense | -29.2M | 3.8M | 1.1M | -28.6M | -29.9M | 59.9M |
Shares Outstanding (Basic) | 93.3M | 90.6M | 82.8M | 80.58M | 77.71M | 74.7M |
Shares Outstanding (Diluted) | 93.3M | 90.6M | 82.8M | 80.6M | 78M | 74.78M |
EPS (Basic) | -3.96 | -1.41 | -3.18 | -1.39 | -0.35 | -2.99 |
EPS (Diluted) | -3.96 | -1.41 | -3.18 | -1.39 | -0.35 | -2.99 |
EBITDA | -330.9M | -59.5M | -197.4M | -84.7M | 12.3M | -123.4M |
EBIT | -384.6M | -120.7M | -259.3M | -137.4M | -50.5M | -194.8M |
Depreciation & Amortization | 53.7M | 61.2M | 61.9M | 52.7M | 62.8M | 71.4M |
Add to Watchlist
Select watchlists to add or remove MYGN